Fusion genes and prostate cancer. From discovery to prognosis and therapeutic perspectives;Gènes de fusion et cancer de la prostate. De la découverte à la valeur pronostique et aux perspectives thérapeutiques

Progres en Urologie

Volumn 19, Issue 11, 2009, Pages 819-824

  Beuzeboc, P ^a   Soulie M ^b   Richaud, P ^c   Salomon, L ^d   Staerman, F ^e   Peyromaure, M ^f   Mongiat Artus, P ^g   Cornud, F ^h   Paparel, P ⁱ   Davin, J L ^j   Molinie V ^a  

^a INSTITUT CURIE   (France)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

^c INSTITUT BERGONIÉ   (France)

^d CHU de Creteil   (France)

^e REIMS UNIVERSITY HOSPITAL   (France)

^f hôpital Cochin ^*  (France)

^g SAINT LOUIS HOSPITAL   (France)

^h Department of Cardiology   (France)

ⁱ Clinique Rhone Durance   (France)

^j HÔPITAL SAINT JOSEPH   (France)

more..

Author keywords

Fusion genes; Prostate cancer; TEMPSS2 ERG

Indexed keywords

GENE FUSION; GENETICS; HUMAN; MALE; PROGNOSIS; PROSTATE TUMOR; SHORT SURVEY;

GENE FUSION; HUMANS; MALE; PROGNOSIS; PROSTATIC NEOPLASMS;

EID: 71649101936     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.purol.2009.06.002     Document Type: Short Survey

References (24)

1. Mitelman F., Johansson B., and Mertens F. The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer 7 4 (2007) 233-245
2. Tomlins S.A., Rhodes D.R., Perner S., Dhanasekaran S.M., Mehra R., Sun X.W., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310 5748 (2005) 644-648
3. Kumar-Sinha C., Tomlins S.A., and Chinnaiyan. Recurrent gene fusions in prostate cancer. Nature Reviews Cancer 8 (2008) 497-509
4. Petrovics G., Liu A., Shaheduzzanan S., et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 24 (2005) 3847-3852
5. Rubin M.A., and Chinnaiyan A.M. Bioinformatics approach leads to the discovery of the TMPRSS2:ETS gene fusion in prostate cancer. Lab Invest 86 11 (2006) 1099-1102
6. Mehra R., Tomlins S.A., Shen R., Nadeem O., Wang L., Wei J.T., et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 20 5 (2007) 538-544
7. Perner S., Demichelis F., Beroukhim R., Schmidt F.H., Mosquera J.M., Setlur S., et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 66 17 (2006) 8337-8341
8. Soller M.J., Isaksson M., Elfving P., Soller W., Lundgren R., and Panagopoulos I. Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. Genes Chromosomes Cancer 45 7 (2006) 717-719
9. Winnes M., Lissbrant E., Damber J.E., and Stenman G. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer. Oncol Rep 17 5 (2007) 1033-1036
10. Wang J., Cai Y., Ren C., and Ittmann M. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res. 66 17 (2006) 8347-8351
11. Lapointe J., Kim Y.H., Miller M.A., Li C., Kaygusuz G., van de Rijn M., et al. A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis. Mod Pathol. 20 4 (2007) 467-473
12. Tomlins S.A., Laxman B., Dhanasekaran S.M., et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448 (2007) 595-599
13. Rouzier C., Haudebourg J., Carpentier X., Valério L., Amiel J., Michiels J.F., et al. Detection of the TMPRSS2-ETS fusion gene in prostate carcinomas: retrospective analysis of 55 formalin-fixed and paraffin-embedded samples with clinical data. Cancer Genet Cytogenet 183 1 (2008) 21-27
14. Laxman B., Tomlins S.A., Mehra R., Morris D.S., Wang L., Helgeson B.E., et al. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia 8 10 (2006) 885-888
15. Cerveira N., Ribeiro F.R., Peixoto A., Costa V., Henrique R., Jeronimo C., et al. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia 8 10 (2006) 826-832
16. Clark J., Merson S., Jhavar S., et al. Diversity of TEMPRSS2-ERG fusion transcripts in the human prostate. Oncogene 26 18 (2007) 2667-2673
17. Mosquera J.M., Perner S., Genega E.M., Sanda M., Hofer M.D., Mertz K.D., et al. Characterisation of TEMPESS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin Cancer Res 145 11 (2008) 3380-3385
18. Mosquera J.M., Perner S., Demichelis F., Kim R., Hofer M., Mertz K., et al. Morphological features of TMPRSS2-ERG gene fusion prostate cancer. J Pathol 212 1 (2007) 91-101
19. Demichelis F., Fall K., Perner S., Andren O., Schmidt F., Setlur S.R., et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26 31 (2007) 4596-4599
20. Attard G., Clark J., Ambroisine L., Fisher G., Kovacs G., Flohr P., et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 27 3 (2008) 253-263
21. Nam R.K., Sugar L., Yang W., Srivasrtava S., Klotz L.H., Yang L.Y., et al. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer 97 (2007) 1690-1695
22. Vlaeminck-Guillem V., Ruffion A., and Andre J. Intérêt du test urinaire PCA3 pour le diagnostic de cancer de prostate. Prog Urol. 18 5 (2008) 259-265
23. Iljin K., Wolf M., Edgren H., Gupta S., Kilpinen S., Skotheim R.I., et al. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve umbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res 66 (2006) 10242-10246
24. Sun C., Dobi A., Mohamed A., Li H., Thangapazham R.L., Furusato B., et al. TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer, activates C-MYC and abrogates prostate epithelial differentiation. Oncogene 27 40 (2008) 5348-5353